Back to Rare Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01048892

NCT01048892
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with one of these cancers (confirmed by a tissue test): neuroblastoma, rhabdomyosarcoma, Wilms tumor, retinoblastoma, adrenocortical carcinoma, or carcinoid tumor
  • Your cancer has come back after treatment or has stopped responding to treatment
  • Your cancer can be measured or detected on scans
  • There are no known treatments that can cure your cancer or meaningfully extend your life with a good quality of life
  • You are able to carry out at least some daily activities (your doctor will assess this using a standard scale)
  • Your blood cell counts, kidney function, liver function, and protein levels meet certain minimum levels (your doctor will check these with blood tests)
  • Your blood oxygen level is above 92% while breathing normal room air
  • You are not pregnant or breastfeeding, and if you could become pregnant or father a child, you are using effective birth control
  • You are fully toilet trained and do not have ongoing problems with daytime or nighttime bladder or bowel control
  • You have fully recovered from the side effects of any previous cancer treatments
  • You have waited the required amount of time since certain past treatments (such as radiation, stem cell transplant, or chemotherapy) before joining the trial
  • You are able to follow the safety monitoring requirements of the study, in the opinion of the study doctor

Who may not be able to join:

  • You have tumors or cancer spread in the lungs that are larger than 5 cm (confirm with trial site)
  • You have significant fluid build-up around the lungs or heart (confirm with trial site)
  • Your cancer started in the brain or spinal cord, or has spread there
  • You have an infection that is not under control
  • You live with someone who is pregnant
  • You have ongoing diarrhea, daytime or nighttime bladder leakage, or a permanent urinary catheter
  • You have had a stem cell transplant and still have signs of graft-versus-host disease (a condition where transplanted cells attack the body)
  • You have received a viral vaccine (including flu shots) in the past 7 days, or would need one during the study
  • You are currently taking part in another experimental drug study or receiving any other cancer treatments at the same time
  • You have previously been treated with the experimental treatment used in this trial (Seneca Valley virus-001)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Children's Oncology Group
Registry
clinicaltrials_gov
Start date
1 September 2009
Est. completion
1 June 2013

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Safety and tolerability; Recommended phase II dose of Seneca Valley virus-001 (NTX-010)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov